Caltech-founded ChromaCode has now raised $42.6m in all for its molecular diagnostics technology business.

ChromaCode, a US-based molecular diagnostics technology spinout of Caltech, secured $28m of series C capital on Tuesday from investors including the institute.
Caltech was joined by VC firm Northpond Ventures, which led the round, as well as Windham Ventures, Moore Venture Partners, New Enterprise Associates, Domain Associates and Okapi Ventures.
Founded in 2012, ChromaCode is developing a molecular analytics platform that combines algorithm-powered software with real-time polymerase chain reaction assays to enhance sample processing in precision medicine settings.